<DOC>
	<DOC>NCT03014947</DOC>
	<brief_summary>This is a phase I, randomized, double-blind, parallel-group trial to compare Investigation Medicinal Product (IMP) MSB11022, US- Reference Product (RP), and EU- Reference Medicinal Product (RMP) (Humira®) in healthy subjects.</brief_summary>
	<brief_title>MSB11022 in Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Healthy male subjects and healthy female subjects of nonchildbearing potential aged 18 to 55 years, inclusive. Other protocol defined inclusion criteria could apply. Concurrent or history infections such as opportunistic infections, including sepsis, pneumonia, and fungal infection. Individuals with history of tuberculosis or diagnosed with tuberculosis by interview, chest Xray examination, or interferongamma release assay. Concurrent or history of demyelinating disease (multiple sclerosis, etc.). Concurrent or history of congestive cardiac failure. Concurrent or history of allergic symptoms such as asthma bronchial, druginduced rash, and urticaria, which, in the judgment of the investigator, may affect participation in this clinical study. Concurrent or history of cardiac, hepatic, renal, gastrointestinal, respiratory, and/or hematological function disorders, which, in the judgment of the investigator or any of the sub investigators, may affect participation in this clinical study. Other protocol defined exclusion criteria could apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>MSB11022</keyword>
	<keyword>Humira®</keyword>
</DOC>